Ocera Therapeutics Company Profile (NASDAQ:TZYM)

About Ocera Therapeutics (NASDAQ:TZYM)

Ocera Therapeutics logoOcera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:TZYM
  • CUSIP: N/A
  • Web: www.ocerainc.com/
P/E:
  • Trailing P/E Ratio:
  • Foreward P/E Ratio: -1.28
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Return on Equity: -183.22%
  • Return on Assets: -95.34%
 
Frequently Asked Questions for Ocera Therapeutics (NASDAQ:TZYM)

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "TZYM."

Who are some of Ocera Therapeutics' key competitors?

Who are Ocera Therapeutics' key executives?

Ocera Therapeutics' management team includes the folowing people:

  • Linda S. Grais M.D. J.D., President, Chief Executive Officer, Director
  • Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Stan Bukofzer M.D., Chief Medical Officer
  • Steven P. James, Lead Independent Director
  • Willard H. Dere M.D., Director
  • Nina S. Kjellson, Independent Director
  • Michael F. Powell Ph.D., Independent Director
  • Anne M. VanLent, Independent Director

How do I buy Ocera Therapeutics stock?

Shares of Ocera Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ocera Therapeutics' stock price today?

One share of Ocera Therapeutics stock can currently be purchased for approximately $0.48.


MarketBeat Community Rating for Ocera Therapeutics (NASDAQ TZYM)
Community Ranking:  3.0 out of 5 (  )
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  76
MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ocera Therapeutics (NASDAQ:TZYM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Ocera Therapeutics (NASDAQ:TZYM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Ocera Therapeutics (NASDAQ:TZYM)
Earnings by Quarter for Ocera Therapeutics (NASDAQ:TZYM)
Earnings History by Quarter for Ocera Therapeutics (NASDAQ TZYM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2013Q4 2012($0.30)($0.18)$1.70 million$1.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.29)($0.16)$1.99 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocera Therapeutics (NASDAQ:TZYM)
Current Year EPS Consensus Estimate: $-0.170 EPS
Next Year EPS Consensus Estimate: $-0.370 EPS

Dividends

Dividend History for Ocera Therapeutics (NASDAQ:TZYM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ocera Therapeutics (NASDAQ:TZYM)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Ocera Therapeutics (NASDAQ:TZYM)
Latest Headlines for Ocera Therapeutics (NASDAQ:TZYM)
Source:
DateHeadline
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Ocera Therapeutics Inc (OCRX)
www.americanbankingnews.com - March 11 at 10:27 PM
americanbankingnews.com logoOcera Therapeutics’ (OCRX) Buy Rating Reiterated at Aegis
www.americanbankingnews.com - March 11 at 8:52 PM
feeds.benzinga.com logo20 Biggest Mid-Day Losers For Monday
feeds.benzinga.com - January 30 at 2:30 PM
feeds.benzinga.com logoOcera Therapeutics Shares Could Rally To $10
feeds.benzinga.com - December 28 at 9:46 AM
feeds.benzinga.com logoOcera Therapeutics To Present Two Preclinical Studies At The International Liver Congress
feeds.benzinga.com - April 15 at 1:32 PM

Social

Chart

Ocera Therapeutics (TZYM) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff